EICHORPublic-registry site landscape for NCT05232071, “Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus”, a NASH - Nonalcoholic Steatohepatitis study sponsored by Inventiva Pharma. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05232071 (registry record) |
| Study title | Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
| Official title | A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) |
| Sponsor | Inventiva Pharma |
| Condition(s) | NASH - Nonalcoholic Steatohepatitis; Diabetes Mellitus, Type 2 |
| Phase | PHASE2 |
| Listed sites | 42 |
| Site countries | United States, Belgium, France, Netherlands, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT05232071.
Eichor generates a preliminary site-risk snapshot for NCT05232071 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other NASH - Nonalcoholic Steatohepatitis trials
← Eichor home · All tracked trials · NASH - Nonalcoholic Steatohepatitis studies · Weekly briefs
